Literature DB >> 15777948

Phosphorothyoate oligodeoxynucleotides block nonspecific binding of Cy5 conjugates to monocytes.

Bernd Jahrsdörfer1, Sue E Blackwell, George J Weiner.   

Abstract

Cy5-based monoclonal antibody conjugates, including those containing PE-Cy5 and Cy5 alone, are used widely for multi-color flow cytometry in both research and clinical applications. One problem with these conjugates is they bind to monocytes and macrophages irrespective of antibody specificity. This effect, which is thought to be due to binding of the Cy5 itself to the human high affinity receptor for IgG (FcgammaRI, CD64), can complicate interpretion of flow cytometric results. In the present study we demonstrate that phosphorothioate oligodeoxynucleotides (PS-ODN) suppress this nonspecific binding in a manner that is independent of PS-ODN sequence. Binding of FITC-labeled PS-ODN to monocytes was blocked by CD64-specific monoclonal antibodies, suggesting CD64 is a PS-ODN-binding protein. We conclude PS-ODN can be used as an effective, simple and low-priced reagent to prevent nonspecific binding of Cy5-based immunoconjugates to monocytes. This effect appears to be mediated by PS-ODN binding to CD64 thereby blocking the binding of Cy5 to this receptor.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15777948     DOI: 10.1016/j.jim.2004.11.023

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  2 in total

1.  PE-Cy5.5 conjugates bind to the cells expressing mouse DEC205/CD205.

Authors:  Chae Gyu Park; Anthony Rodriguez; Ralph M Steinman
Journal:  J Immunol Methods       Date:  2012-07-25       Impact factor: 2.303

2.  Tumor necrosis factor alpha neutralization attenuates immune checkpoint inhibitor-induced activation of intermediate monocytes in synovial fluid mononuclear cells from patients with inflammatory arthritis.

Authors:  Anne Sofie Sørensen; Morten Nørgaard Andersen; Kristian Juul-Madsen; Amalie Dyrelund Broksø; Cæcilie Skejø; Henrik Schmidt; Thomas Vorup-Jensen; Tue Wenzel Kragstrup
Journal:  Arthritis Res Ther       Date:  2022-02-14       Impact factor: 5.156

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.